These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 16942444)

  • 21. Gene therapy restores vision in a canine model of childhood blindness.
    Acland GM; Aguirre GD; Ray J; Zhang Q; Aleman TS; Cideciyan AV; Pearce-Kelling SE; Anand V; Zeng Y; Maguire AM; Jacobson SG; Hauswirth WW; Bennett J
    Nat Genet; 2001 May; 28(1):92-5. PubMed ID: 11326284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of tolerance to lentiviral LV-RPE65 gene therapy vector after subretinal delivery in non-human primates.
    Matet A; Kostic C; Bemelmans AP; Moulin A; Rosolen SG; Martin S; Mavilio F; Amirjanians V; Stieger K; Lorenz B; Behar-Cohen F; Arsenijevic Y
    Transl Res; 2017 Oct; 188():40-57.e4. PubMed ID: 28754419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal retinal architecture in a 33-week-old fetus with LCA and a homozygous C330Y mutation in RPE65.
    Koenekoop RK
    Ophthalmic Genet; 2003 Jun; 24(2):125-6. PubMed ID: 12789577
    [No Abstract]   [Full Text] [Related]  

  • 24. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.
    Cideciyan AV; Aleman TS; Boye SL; Schwartz SB; Kaushal S; Roman AJ; Pang JJ; Sumaroka A; Windsor EA; Wilson JM; Flotte TR; Fishman GA; Heon E; Stone EM; Byrne BJ; Jacobson SG; Hauswirth WW
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15112-7. PubMed ID: 18809924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA).
    Pang JJ; Chang B; Hawes NL; Hurd RE; Davisson MT; Li J; Noorwez SM; Malhotra R; McDowell JH; Kaushal S; Hauswirth WW; Nusinowitz S; Thompson DA; Heckenlively JR
    Mol Vis; 2005 Feb; 11():152-62. PubMed ID: 15765048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impacts of two point mutations of RPE65 from Leber's congenital amaurosis on the stability, subcellular localization and isomerohydrolase activity of RPE65.
    Chen Y; Moiseyev G; Takahashi Y; Ma JX
    FEBS Lett; 2006 Jul; 580(17):4200-4. PubMed ID: 16828753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency.
    Pang J; Boye SE; Lei B; Boye SL; Everhart D; Ryals R; Umino Y; Rohrer B; Alexander J; Li J; Dai X; Li Q; Chang B; Barlow R; Hauswirth WW
    Gene Ther; 2010 Jul; 17(7):815-26. PubMed ID: 20237510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy for Leber congenital amaurosis.
    Bennett J
    Novartis Found Symp; 2004; 255():195-202; discussion 202-7. PubMed ID: 14750605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
    Stein L; Roy K; Lei L; Kaushal S
    Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of gene transfer for Leber's congenital amaurosis.
    Maguire AM; Simonelli F; Pierce EA; Pugh EN; Mingozzi F; Bennicelli J; Banfi S; Marshall KA; Testa F; Surace EM; Rossi S; Lyubarsky A; Arruda VR; Konkle B; Stone E; Sun J; Jacobs J; Dell'Osso L; Hertle R; Ma JX; Redmond TM; Zhu X; Hauck B; Zelenaia O; Shindler KS; Maguire MG; Wright JF; Volpe NJ; McDonnell JW; Auricchio A; High KA; Bennett J
    N Engl J Med; 2008 May; 358(21):2240-8. PubMed ID: 18441370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs.
    Bruewer AR; Mowat FM; Bartoe JT; Boye SL; Hauswirth WW; Petersen-Jones SM
    PLoS One; 2013; 8(4):e60218. PubMed ID: 23560080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA.
    Jacobs JB; Dell'Osso LF; Wang ZI; Acland GM; Bennett J
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4685-92. PubMed ID: 19458334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis.
    Li X; Li W; Dai X; Kong F; Zheng Q; Zhou X; Lü F; Chang B; Rohrer B; Hauswirth WW; Qu J; Pang JJ
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):7-15. PubMed ID: 21169527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.
    Cideciyan AV; Hauswirth WW; Aleman TS; Kaushal S; Schwartz SB; Boye SL; Windsor EA; Conlon TJ; Sumaroka A; Pang JJ; Roman AJ; Byrne BJ; Jacobson SG
    Hum Gene Ther; 2009 Sep; 20(9):999-1004. PubMed ID: 19583479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human cone photoreceptor dependence on RPE65 isomerase.
    Jacobson SG; Aleman TS; Cideciyan AV; Heon E; Golczak M; Beltran WA; Sumaroka A; Schwartz SB; Roman AJ; Windsor EA; Wilson JM; Aguirre GD; Stone EM; Palczewski K
    Proc Natl Acad Sci U S A; 2007 Sep; 104(38):15123-8. PubMed ID: 17848510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological Amelioration of Cone Survival and Vision in a Mouse Model for Leber Congenital Amaurosis.
    Li S; Samardzija M; Yang Z; Grimm C; Jin M
    J Neurosci; 2016 May; 36(21):5808-19. PubMed ID: 27225770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel.
    Banin E; Bandah-Rozenfeld D; Obolensky A; Cideciyan AV; Aleman TS; Marks-Ohana D; Sela M; Boye S; Sumaroka A; Roman AJ; Schwartz SB; Hauswirth WW; Jacobson SG; Hemo I; Sharon D
    Hum Gene Ther; 2010 Dec; 21(12):1749-57. PubMed ID: 20604683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
    Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
    Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.
    Simonelli F; Maguire AM; Testa F; Pierce EA; Mingozzi F; Bennicelli JL; Rossi S; Marshall K; Banfi S; Surace EM; Sun J; Redmond TM; Zhu X; Shindler KS; Ying GS; Ziviello C; Acerra C; Wright JF; McDonnell JW; High KA; Bennett J; Auricchio A
    Mol Ther; 2010 Mar; 18(3):643-50. PubMed ID: 19953081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retinal disease in Rpe65-deficient mice: comparison to human leber congenital amaurosis due to RPE65 mutations.
    Caruso RC; Aleman TS; Cideciyan AV; Roman AJ; Sumaroka A; Mullins CL; Boye SL; Hauswirth WW; Jacobson SG
    Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5304-13. PubMed ID: 20484585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.